Stux Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Stux Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$871K	Sell	9,200 -1,800	-16%	-$126K	0.11%	230
2014 Q1	$778K	Sell	11,000 -700	-6%	-$55.4K	0.1%	235
2013 Q4	$869K	Buy	11,700 +200	+2%	+$13.9K	0.1%	220
2013 Q3	$872K	Sell	11,500 -500	-4%	-$39.8K	0.12%	201
2013 Q2	$961K	Buy	+12,000	New	+$884K	0.12%	201

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stux Capital Management's VRTX Position: Q2 2014 in Review

Stux Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2014, selling an estimated $126K and leaving 9,200 shares worth $871K. The position accounts for 0.11% of the portfolio, ranked #230.

Stux Capital Management first reported a position in VRTX in Q2 2013 and has held it in 5 quarters since. The position peaked at $961K in Q2 2013. 411 funds tracked by Wall St. Rank hold VRTX as of Q2 2014.

Stux Capital Management held 9,200 shares of Vertex Pharmaceuticals worth $871K as of Q2 2014.
Stux Capital Management sold 1,800 Vertex Pharmaceuticals shares in Q2 2014, an estimated $126K.
Vertex Pharmaceuticals made up 0.11% of Stux Capital Management's portfolio in Q2 2014, its #230 holding.
Stux Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
Stux Capital Management's Vertex Pharmaceuticals position peaked at $961K in Q2 2013.
411 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2014.

Based on Stux Capital Management's 13F filing for Q2 2014, filed 14 Jul 2014.